Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT ID: NCT01305993
Last Updated: 2011-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
26 participants
INTERVENTIONAL
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer
NCT00580359
A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma
NCT00980382
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209664
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
NCT00343668
Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
NCT00587145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SB injection
Infusion SBinjection of 21.87ml/m\^2, IV route, 24times for 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage and with measurable lesions
* Life expectancy \>/= 5 months
* Not available to any of resectable surgery or radiotherapy
* Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as defined by
1. Absolute neutrophil count(ANC)\>/= 1.0 x 10\^9/L, Platelet count \>/= 75 x 10\^9/L
2. Total bilirubin \< 2.0mg/dL
3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) \< 5 x Upper Limit Normal(ULN)
4. creatinine \< 2 x ULN
* ECOG status 0 to 2
* Female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7days ago
* Patients or their legal representatives who have signed the informed consent form.
Exclusion Criteria
* Patients who have received chemotherapy within the previous 4 weeks
* Patients who have received radiotherapy related tp Gastric cancer within 4weeks
* Patients who have participated in other clinical study within the previous 4weeks
* Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
* Human immunodeficiency virus(HIV) antibody (+)
* Have active infection or serious concomitant systemic disorder incompatible with the study
* Clinically hypertension or diabete mellitus not well controlled with medication
* Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction
* Presence or history of malignancy other than Gastirc cancer within 5years
* Have severe Neurologic or psychological disorder
* Patients who have history of allery with this investigational drug(SB injection)
* Obvious cognitive or physical impairment that would prevent participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SBPharmaceutical IND, Co., LTD
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SBPharmaceutical IND, Co., LTD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yong-oon Shin, Prof
Role: PRINCIPAL_INVESTIGATOR
Inha University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inha University Hospital
Incheon, Jung-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SB injection-G002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.